Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00439543
Recruitment Status : Unknown
Verified February 2007 by Interstitial Lung Disease Study Group, Korea. Recruitment status was: Not yet recruiting
Idiopathic pulmonary fibrosis(IPF) is chronic progressive fibrosing lung disease of unknown cause. There is no effective therapy yet for this disease and the mean survival in most reports is about 3 years after the diagnosis. Because of the stiff fibrosis of the lung, pulmonary hypertension is the late complication of IPF and its development heralds a very poor outcome of the patients. For the primary pulmonary hypertension, recently the effective drugs have been available. However, there is no study about the efficacy of these drugs in the patients with pulmonary hypertension secondary to pulmnary fibrosis, and the aim of this trial is to study the safty and efficacy of "Iloprost," one of the safe and effective drugs in primary pulmonary hypertension.
Condition or disease
Pulmonary FibrosisPulmonary Hypertension
Drug: Iloprost inhalation
Phase 2Phase 3
Prospective open labeled observational study
Subjects: About 15 patients with secondary pulmonary hypertension due to IPF or pulmonary fibrosis associated with collagen vascular diseases.
Method: 3 month trial of inhaled iloprost. Check the safty and measure the pulmonary arterial pressure by right heart catheterization, exercise capacity by 6 minute walking test, echocardiography, and quality of life questionnaires before and after the trial.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosis of idiopathic pulmonary fibrosis or fibrotic NSIP according to American Thoracic Society and European Respiratory Society guidelines by biopsy and diagnosis of pulmonary fibrosis associated with connective tissue disease.
Mean pulmonary artery pressure over 30mmHg.
NYHA functional class II to IV
Suffering lung diseases other than pulmonary fibrosis (COPD, Pulmonary Thromboendarterectomy ).
Administration of prostanoids, bosentan, beta- blocker or phosphodiesterase5 inhibitor.
Dosage adjustment of calcium channel blockers within 6 weeks.
Resting pulmonary capillary wedge pressure over 15mmHg.
Bilirubin level above 3mg/dl or creatinine clearance level below 30ml/min.
Unstable angina pectoris, myocardial infarction or severe arrhythmia within 6 months.